| Bioactivity | LXQ-217 is an oral active SHP2 inhibitor with the IC50 of 2.01 μM. LXQ-217 induces apoptosis and inhibits cell growth in vivo and in vitro[1]. |
| Invitro | LXQ-217 (72 h) 对 A549、HCT116、HepG2 和 MDA-MB-231 细胞有抑制作用，IC50 值分别为 2.06、3.88、4.53 和 5.13 μM[1]。LXQ-217 (2.5, 5, 10 μM, 7 days) 可以降低 A549 细胞的克隆数量和形成率[1]。LXQ-217 (1.25, 2.5 μM, 24 h) 抑制 A549 细胞的迁移[1]。LXQ-217(2.5、5、10 μM, 3 h) 增加 A549 细胞中切割-parp (C-parp)、切割-caspase9 (C-cas9) 和切割-caspase3 (C-cas3) 的蛋白水平[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> LXQ-217 相关抗体: Cell Migration Assay [1] Cell Line: |
| In Vivo | LXQ-217 (50, 100mg/kg; Oral administration for 14 days) 可抑制 BALB/c 裸鼠构建的 A549 细胞异种移植模型的生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 2524718-79-2 |
| Formula | C24H20Br2N2O5 |
| Molar Mass | 576.23 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sun H, et al. Small Molecule SHP2 Inhibitor LXQ-217 affects Lung Cancer Cell Proliferation in Vitro and in Vivo. Chem Biodivers. Published online February 20, 2024. |